Hodgkin disease with subsequent transformation to CD30 positive non- Hodgkin lymphoma in six patients

Cancer

Volumn 85, Issue 4, 1999, Pages 970-979

  Mori, Naoyoshi ^a   Watanabe, Kazuko ^a   Yamashita, Yoriko ^a   Nakayama, Atsuo ^a   Yatabe, Yasushi ^b   Narita, Michihiko ^c   Kobayashi, Toshitaka ^d   Hasegawa, Yuuichi ^e   Kojima, Hiroshi ^e   Nagasawa, Toshiro ^e  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Kamo Hospital   (Japan)

^d TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anaplastic large cell lymphoma; Epstein Barr virus encoded RNA; Granzyme B; Hodgkin disease; Latent membrane protein 1 (LMP 1); p80; Pancadherin; Perforin

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; CD15 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; DNA; EPITHELIAL MEMBRANE ANTIGEN; GRANZYME B; LATENT MEMBRANE PROTEIN 1; LEUKOSIALIN; PERFORIN; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SOUTHERN BLOTTING; TUMOR BIOPSY;

ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REED-STERNBERG CELLS; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL; VIRAL MATRIX PROTEINS;

EID: 0033558007     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<970::AID-CNCR27>3.0.CO;2-L     Document Type: Article

References (59)

1. Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988;12:264-74.
2. Chott A, Kascrer K, Augustin I, Vesely M, Heinz R, Ochlinger W, et al. Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol 1990;14:439-48.
3. Nakamura S, Takagi N, Kojima M, Motoori T, Kitoh K, Osada H, et al. Clinicopathologic study of large cell anaplastic lymphoma (Ki-1 positive large cell lymphoma) among the Japanese. Cancer 1991;68:118-29.
4. +): results of a prospective clinico-pathological study of 69 cases. Br J Haematol 1994;86:513-23.
5. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58.
6. Bullrich F, Morris SW, Hummel M, Pileri S, Stein H, Croce CM. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas. Cancer Res 1994;54:2873-7.
7. Downing JR, Ladanyi M, Raffeld M, Weiss LM, Marris S W. Large-cell anaplastic lymphoma-specific translocation in Hodgkin disease. Lancet 1995;345:918-9.
8. Elmberger PG, Lozano MD, Weisenberger DD, Sanger W, Chan WC. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin disease, and reactive lymphoid lesions. Blood 1995;86:3517-21.
9. Filippa DA, Ladanyl M, Wollner N, Straus DJ, O'Brien JP, Portlock C, et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin disease. Blood 1996;87:2905-17.
10. Orscheschek K, Merz H, Hell J, Binder T, Bartels H, Feller AC. Large-cell anaplastic lymphoma-specific translocation t(2;5)(p23;q35) in Hodgkin disease: indication of a common pathogenesis? Lancet 1995;345:87-90.
11. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, et al. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23; q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin lymphomas, Hodgkin disease, or lymphomatoid papulosis. Blood 1996;88:1771-9.
12. Weisenberger DD, Gordon BG, Vose JM, Bast MA, Chan WC, Greiner TC, et al. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin lymphoma. Blood 1996;87:3860-8.
13. + anaplastic large-cell lymphomas, in other non-Hodgkin lymphomas of the T-cell phenotype, and in Hodgkin disease. Blood 1995;86:2321-8.
14. Yee HT, Ponzoni M, Merson A, Goldstein M, Scarpa A, Chilosi M, et al. Molecular characterization of the t(2;5)(p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin disease. Blood 1996;87:1081-8.
15. Agnarsson GA, Kadin ME. The immunophenotype of Reed-Sternberg cells: a study of 50 cases of Hodgkin disease using fixed frozen tissues. Cancer 1989;63:2083-9.
16. Dorreen MS, Habeshaw JA, Stansfeld AG, Wringley PF, Lister TA. Characteristics of Sternberg-Reed and related cells in Hodgkin disease. Br J Cancer 1984;49:465-76.
17. Hell K, Pringle JH, Hansmann ML, Lorenzen J, Colloby P, Lauder I, et al. Demonstration of light chain mRNA in Hodgkin disease. J Pathol 1993;171:137-43.
18. Korkopoulou P, Cordell J, Jones M, Kaklamanis L, Tsenga A, Gatter KC, et al. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin disease. Histopathology 1994;24:511-55.
19. Leoncini L, DelVecchio MT, Kraft R, Megha T, Barbini P, Cevenini G, et al. Hodgkin disease and CD30-positive anaplastic large cell lymphomas - a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. Am J Pathol 1990;137:1047-57.
20. Harris NL. The relationship between Hodgkin disease and non-Hodgkin lymphoma. Semin Diagn Pathol 1992;4:304-10.
21. Del Mistro A, Leszl A, Bertorelle R, Calabro ML, Panozzo M, Menin C, et al. A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin disease. Leukemia 1994;8:1214-9.
22. Pileri S, Mazza P, Zinzani PL, Poggi S, Polleti G, Falini B, et al. Ki-1 lymphoma and Hodgkin disease. Hematologica 1989;74:333-4.
23. Harris NL, Jaffe ES, Stein H, Banks P, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms; a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
24. Jaffe ES. Surgical pathology of the lymph nodes and related organs. 2nd edition. Philadelphia: WB Sanders, 1995:230-1.
25. Mclean IW, Nakane PK. Periodate-lysine-paraformaldehyde fixative: a new fixative for immunoelectron microscopy. J Histochem Cytochem 1974;22:1077-83.
26. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody procedures. J Histochem Cytochem 1981;29:577-80.
27. Chang, KL, Chen YY, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992;1: 246-55.
28. Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, et al. Epstein-Barr virus latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma: correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993;143:1072-85.
29. Tokunaga M, Imai S, Uemura Y, Tokudome T, Osato T, Sato E. Epstein-Barr virus in adult T-cell leukemia/lymphoma. Am J Pathol 1993;143:1263-9.
30. Weiss LM, Chen Y-Y, Liu X-F, Shibata D. Epstein-Barr virus and Hodgkin disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991;139: 1259-65.
31. Wu T-C, Mann RB, Epstein JI, McMahon E, Lee WT, Charache P, et al. Abundant expression of EBER-1 small nuclear RNA in nasopharyngeal carcinoma: a morphologically distinct target for detection of Epstein-Barr virus in formalin-fixed, paraffin-embedded carcinoma specimens. Am J Pathol 1991;138:1461-9.
32. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:9.14-9.19.
33. Strickler JG, Michie SA, Warnke RA, Dorfman RF. The syncytial variant of nodular sclerosing Hodgkin disease. Am J Surg Pathol 1986;10:470-7.
34. MacLennan KA, Bennett MH, Tu A, Hudson BV, Easterling J, Hudson GV, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin disease. Cancer 1989;64:1686-93.
35. Sundeen JT, Cossman J, Jaffe ES. Lymphocyte predominant Hodgkin disease nodular subtype with coexistent large cell lymphoma. Histological progression or composite malignancy? Am J Surg Pathol 1988;12:599-606.
36. Frizzera G. The distinction of Hodgkin disease from anaplastic large cell lymphoma. Semin Diag Pathol 1992; 4:291-6.
37. Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988;130:59-70.
38. NPM/ALK; a distinct clinicopathologic entity. Blood 1995;86:1954-60.
39. Foss HD, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996;88:4005-11.
40. Mori N, Yatabe Y, Oka K, Kinoshita T, Kobayashi T, Ono T, et al. Expression of perforin in nasal lymphoma: additional evidence of its natural killer cell derivation. Am J Pathol 1996;149:699-705.
41. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: Potential diagnostic markers for activated cytotoxic cells. Immunol Today 1991;12:415-9.
42. Heusel JW, Wesselschmidt RL, Shresta S, Russel JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994;76:977-87.
43. Nakajima H, Park L, Henkart PA. Synergistic roles of granzymes A and B in mediating target cell death by RBL mast cell tumors also expressing cytolysin/perforin. J Exp Med 1995;181:1037-46.
44. Shi L, Kam CM, Powers JC, Aebersold R, Greenberg AH. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med 1992;176:1521-9.
45. Krenacs L, Wellmann A, Sorbata L, Himmelmann AW, Bagdi E, Jaffe ES, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T-and null-cell type and Hodgkin disease: evidence for distinct cellular origin. Blood 1997;89:980-9.
46. Oudejans JJ, Kumar JA, Jiwa M, van der Valk P, Ossenkoppele GJ, Kluin PM, et al. Granzyme B expression in Reed-Sternberg cells of Hodgkin disease. Am J Pathol 1996;148: 233-40.
47. Ashton-Key MA, Cowley GP, Smith MEF. Cadherins in reactive lymph nodes and lymphomas: high expression in anaplastic large cell lymphomas. Histopathology 1996;28:55-9.
48. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin disease. N Engl J Med 1989;320:502-6.
49. Wu T-C, Mann RB, Charache P, Hayward D, Staal S, Lambe BC, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin disease. Int J Cancer 1990;46:801-4.
50. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991;88:4766-70.
51. Pinkus GS, Lones M, Shintaku IP, Said JW. Immunohistochemical detection of Epstein-Barr virus-encoded latent membrane protein in Reed-Sternberg cells and variants of Hodgkin disease. Mod Pathol 1994;7:454-61.
52. Brousset P, Rochaix P, Chittal S, Rubie H, Robert A, Delsol G. High incidence of Epstein-Barr virus detection in Hodgkin disease and absence of detection in anaplastic large-cell lymphoma in children. Histopathology 1993;23:189-91.
53. Lopategui JR, Gaffey MJ, Chan JKC, Frierson HF, Sun L-H, Bellafiore FJ, et al. Infrequent association of Epstein-Barr virus with CD30-positive anaplastic large cell lymphomas from American and Asian patients. Am J Surg Pathol 1995; 19:42-9.
54. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Finn T, Young LS, et al. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphomas. Blood 1991;78:2666-73.
55. Kanavaros P, Jiwa NM, De Bruin PC, van der Valk, Noorduyn LA, van Heerde P, et al. High incidence of EBV genome in CD30-positive non-Hodgkin lymphomas. J Pathol 1992;168: 307-15.
56. Kant JA, Hubbard SM, Longo DL, Simon RM, DeVita VY, Jaffe ES. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin disease. J Clin Oncol 1986;4:284-94.
57. Kobayashi T, Nagasawa T, Mitsuhashi S, Hasegawa Y, Kojima H, Ninomiya H, et al. Clinicopathological characteristics of primary Ki-1 anaplastic large-cell lymphoma. Int J Haematol 1996;63:41-50.
58. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:284-94.
59. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 1996;14:955-62.